Ruxolitinib Adverse Event Data and Strategies for Managing Side Effects
Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.
EP: 1.Introduction: A 58-Year-Old Man With Moderate Steroid-Refractory cGVHD and Risk Factors for cGVHD
EP: 2.Overview of cGVHD Symptoms, Diagnosis, and Tools for Severity Assessment
EP: 3.Steroid-Refractory cGVHD: Risk Factors and Clinical Challenges
EP: 4.Treatment Options for Steroid-Refractory cGVHD
EP: 5.Ruxolitinib in Steroid-Refractory cGVHD and REACH3 Efficacy Data
EP: 6.Real-World Efficacy Data for Ruxolitinib in Steroid-Refractory cGVHD
Now Viewing
EP: 7.Ruxolitinib Adverse Event Data and Strategies for Managing Side Effects
EP: 8.Case Commentary and Considerations for Treatment and Management
EP: 9.Future Directions in GVHD
Case: A 58-Year-Old Man With Moderate Steroid-Refractory Chronic Graft-Versus-Host Disease
Initial Presentation
- A 58-year-old man previously underwent myeloablative conditioning and an allogeneic PBSC transplant for acute lymphocytic leukemia
- Received tacrolimus and methotrexate for GVHD prophylaxis
- At 10 months post-transplant, patient developed moderate muscle and joint pain with decreased range of motion, mild erythematous rash on cheeks
First-line Treatment
- Patient received topical steroid cream for rash, and was started on oral prednisone at 1 mg/kg/day
- After 4 weeks of treatment, the patient’s rash resolved but muscle/joint pain continued
Second-line Treatment
- Patient is now receiving ruxolitinib 10 mg orally twice daily, alongside 1 mg/kg/day steroids
Related Videos
Related Content
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Article
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More
